A landmark trial led by UCLA Health investigators has demonstrated that combining a targeted therapy drug Zanzalintinib with an immune checkpoint inhibitor Atezolizumab significantly improved survival in patients with metastatic Colorectal cancer who had microsatellite-stable disease (MSS)—a subgroup that historically responds poorly to immunotherapy. The study enrolled 901 patients across 121 sites in 16 countries. Source
After ~18 months of follow-up, the median overall survival (OS) in the combination arm was 10.9 months versus 9.4 months in the standard-therapy arm, representing a 20 % reduction in risk of death. Approximately 20 % of patients in the combination arm were alive at 2 years compared to 10 % in the control group. Source
This data is transformative for colorectal cancer treatment because it demonstrates benefit from immunotherapy in the large MSS subgroup, moving beyond the small fraction previously benefiting from immune checkpoint inhibitors. For oncologists, these results support earlier consideration of combined targeted and immunotherapy regimens in metastatic colorectal cancer.
Overall, this research opens new therapeutic frontiers in one of the most common and lethal cancers, offering improved survival and hope for patients with previously limited options.
Copyright © All rights reserved – Salute33